

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C07G 7/00	A1	(11) International Publication Number: WO 79/00299 (43) International Publication Date: 31 May 1979 (31.05.79)
(21) International Application Number: PCT/GB78/00038 (22) International Filing Date: 10 November 1978 (10.11.78) (31) Priority Application Number: 47933/77 (32) Priority Date: 17 November 1977 (17.11.77) (33) Priority Country: GB	(71) Applicants: THE UNITED KINGDOM ATOMIC ENERGY AUTHORITY; 11 Charles II Street, London, United Kingdom SW1Y 4QP (for all designated States except US). MATTOCK, Patrick; 28 Evans Road, Eynsham, Oxon., United Kingdom (for US only). (72) Inventor: MATTOCK, Patrick; 28 Evans Road, Eynsham, Oxon., United Kingdom. (74) Agent: MANSELL, Keith, Rodney; Patents Branch, United Kingdom Atomic Energy Authority, 11 Charles II Street, London, United Kingdom SW1 4QP. (81) Designated States: DE, GB, SE, US. Published with: <i>International search report</i>	
(54) Title: PURIFICATION OF FACTOR VIII (57) Abstract <p>Purification of Factor VIII containing solutions, such as blood plasma, by continuous flow electrophoresis. Hitherto, purification of such solutions has been performed by methods such as cryoprecipitation which however have the disadvantages of poor recovery. In our invention, this problem is overcome by adjusting the pH of a Factor VIII containing solution to be in a range where the stability of Factor VIII is not adversely affected (e.g. 6 to 9) and then subjecting the solution to continuous flow electrophoresis to give purified Factor VIII fractions. If desired, the fractions may be further purified.</p>		

BEST AVAILABLE COPY

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AT	Austria	LU	Luxembourg
BR	Brazil	MC	Monaco
CF	Central African Empire	MG	Madagascar
CG	Congo	MW	Malawi
CH	Switzerland	NL	Netherlands
CM	Cameroon	SE	Sweden
DE	Germany, Federal Republic of	SN	Senegal
DK	Denmark	SU	Soviet Union
FR	France	TD	Chad
GA	Gabon	TG	Togo
GB	United Kingdom	US	United States of America
JP	Japan		

- 1 -

Purification of Factor VIII

## TECHNICAL FIELD

This invention relates to the purification of Factor VIII containing solutions, such as blood plasma, by continuous flow electrophoresis.

## BACKGROUND ART

Factor VIII is the antihaemophilic factor in blood. Its actual structure is, at present, unknown though it is suspected to be a complex high molecular weight protein or possibly associated with such a protein. There is much interest in its extraction, e.g. from blood plasma, so that it can be used in the treatment of patients suffering from haemophilia. Factor VIII is, however, unstable and this has created difficulties in its extraction. Methods of extraction are, however, available such as a cryoprecipitation method. This method has the disadvantage of poor recovery (e.g. about 40%) of Factor VIII from the initial plasma and of giving rise to a dilute product, which accordingly creates problems of administration to the patient because of the large volume of product required to achieve suitable dose levels. The dilute product may, however, if required, be further purified and freeze dried to give a concentrated form of Factor VIII, but with further loss of Factor VIII activity.



- 2 -

## DISCLOSURE OF INVENTION

We have now devised a method of extracting Factor VIII from blood plasma and other Factor VIII containing solutions, such as partly purified blood plasma, which, we believe, substantially overcomes the abovementioned problems. Our method includes the application of continuous flow electrophoresis to Factor VIII extraction.

The present invention provides a method of purifying a Factor VIII containing aqueous solution characterised by the steps of

- (i) reducing the ionic strength of the solution to a level such that it is capable of being electrophoresed;
- (ii) adjusting the pH of the solution to within a range where the stability of Factor VIII is not adversely affected;
- (iii) subjecting the product of step (ii) to continuous flow electrophoresis by injecting the solution as a migrant solution into a second aqueous solution laminarly flowing in an annular separation chamber as a carrier solution for the migrant solution and stabilised by means of an angular velocity gradient, and applying a constant electric field across the resulting mixture to produce a differential movement of the Factor VIII component of the migrant solution with respect to the other major components of the solution perpendicular to the direction of flow of the layer; and
- (iv) collecting the separated Factor VIII component.

If desired, the separated Factor VIII component, which is in aqueous solution, may be further purified, for example, by freeze drying, redissolving in water, adjusting the pH to 7 and removing insoluble material or preferably by



- 3 -

concentrating using a hollow fibre concentrator before freeze drying. In specific examples, we have achieved an overall recovery of at least 60% from the initial plasma with a 14-fold purification over the initial plasma. Also, we have  
5 found that the final product contains virtually no fibrinogen, whilst the major contaminant is albumin which, we believe, however, may have little effect upon the Factor VIII.

Step (i) of our method has to be carried out in order  
10 to be able to carry out step (iii). A number of methods may be used in step (i) such as gel filtration and dialysis. We prefer to use dialysis because of its simplicity and because it causes no detectable loss of Factor VIII activity in Factor VIII containing solutions such as blood plasma.

15 The product of step (i) may in some cases require dilution before it can be used in subsequent steps (ii) and (iii) in order to lower the protein concentration to a level suitable for electrophoresis to be carried out.

Step (iii) is most conveniently carried out as  
20 generally described in U.K. Patent Specification No. 1 186 184 (corresponding to U.S. Patent No. 3 616 453), which describes a process and apparatus where stabilisation of flowing streams in continuous flow electrophoresis is effected by an angular velocity gradient. Thus, in our  
25 method, the fractionation may be effected in an annular separation chamber defined between a central stationary cylinder (a stator) and an outer rotating cylinder (a rotor), which results in a gradient of angular velocity across the annular chamber giving laminar flow at high throughputs.  
30 The constant electric field is then applied across the annular chamber to produce the differential movement of the Factor VIII component of the migrant solution. Improvements and/or modifications of the apparatus described



- 4 -

in U.K. Patent Specification No. 1 186 184 are described in U.K. Patent Specification Nos. 1 431 887 and 1 431 888 (corresponding to U.S. Patent No. 3 844 926).

5 The pH of the migrant solution in step (iii) may suitably be in the range of 6 to 9 though we generally prefer that it is in the range of 7 to 8.5. The adjustment of the pH of the product of step (i) in step (ii) may suitably be carried out by means of an appropriate buffer solution. pH has to be adjusted as in step (ii) because of  
10 its effect on stability of Factor VIII. Thus, Factor VIII is stable at pH 7, but its stability decreases as the pH moves away from 7. However, if the residence time of the migrant solution under the conditions of step (iii) is short, it may be possible to carry out the step at pH's  
15 remote from 7. A further consideration is that, at pH's approaching 7, more electrical power is required to produce a given mobility of a component of the migrant solution because of its net charge and this may give rise to heating such as to affect the stability of the Factor  
20 VIII. Taking these conflicting requirements into account, we particularly prefer that the pH of the migrant solution is 7.5. A further preferment is that the electrical conductivity of the migrant solution is in the range of 0.75 to 1.0 mScm<sup>-1</sup> at 20°C.

25 Step (iv) may be carried out as described in U.K. Patent Specification Nos. 1 431 887 and 1 431 888. Thus, if our method is carried out as described in these specifications, the direction of migration of the migrant solution is centrifugal and the injection thereof accordingly  
30 effected at the inner side of the flow of the carrier solution. The direction of flow is generally upward and is helical in pattern because of the effect of the rotation of the rotor. Separated components may then be collected by



- 5 -

means of an off-take system located in the stator and consisting of a series of parallel mazeplates with spacers. A particular separated component may then pass through one or more particular mazeplates and hence into collecting tube(s).

- 5        The invention also provides Factor VIII obtained by the present method.

#### BEST MODE FOR CARRYING OUT THE INVENTION

##### Example 1

- 10        Fresh, frozen human blood plasma (250 ml) was thawed rapidly and dialysed overnight against an aqueous tris-citrate solution (10L; pH 7.0; conductivity  $0.75 \text{ mScm}^{-1}$ ) at  $4^{\circ}\text{C}$  in order to reduce the salt concentration of the plasma. The dialysed plasma was then diluted approximately 1.5 times with an aqueous tris-citrate solution to give a product of  
15        pH 7.5 and an electrical conductivity of  $1.0 \text{ mScm}^{-1}$  at  $20^{\circ}\text{C}$ .

- 20        The above product, as a migrant solution, was then warmed to  $20^{\circ}\text{C}$  and electrophoresed using a continuous electrophoretic separation apparatus of the type generally described in U.K. Patent Specification Nos 1 431 887 and 1 431 888. The apparatus had 29 outlet ports, a stator radius of 40 mm, a rotor radius of 45 mm to give an annular gap of 5 mm, and electrodes 304 mm in length. A carrier solution at  $2^{\circ}\text{C}$  comprising an aqueous tris-citrate solution (pH 7.5: electrical conductivity  $0.75 \text{ mScm}^{-1}$  at  $20^{\circ}\text{C}$ )  
25        was passed upwardly through the annular gap at a rate of 500 ml/minute and the flow stabilised by rotation of the rotor. The migrant solution was injected into the annular gap at a rate of 10 ml/minute. The electrophoresis was carried out at 35 amps and 27 volts giving a temperature rise of  
30        carrier solution of  $20^{\circ}\text{C}$ , i.e., from  $2^{\circ}\text{C}$  to  $22^{\circ}\text{C}$ . The electrolytes were ammonium acetate (1M; pH 7.5) for the



cathode and an equal volume mixture (pH 7.5) of ammonium citrate (0.2 M) and ammonium phosphate (0.15 M) for the anode. Separated components containing Factor VIII activity as judged by a one-stage assay procedure were collected and  
5 those containing about 75% of the total Factor VIII clotting activity (which was from 4 to 5 of the outlets) were pooled together, freeze dried and stored at  $-25^{\circ}\text{C}$ . The one-stage assay procedure used was as described in American Journal of Chemical Pathology, Vol. 61 No. 2 February 1974:  
10 "Reassessment of a Non-Haemophilic Reagent for Factor VIII (AHF) Determination" by de Angula & Frommel.

The above freeze dried product was redissolved in about 1/30th of the volume, from electrophoresis, of distilled water to give a concentration of about 15 mg/ml of protein, the pH  
15 adjusted to 7 using dilute ammonia solution and insoluble material removed by centrifugation at 15000 r.p.m. for 15 minutes. A further one-stage assay as above showed that about 80% of the Factor VIII activity of the pooled components had been recovered. Thus, the overall recovery from the  
20 initial plasma was at least 60%, with a 14-fold purification over the initial plasma in relation to protein concentration.

The final product contained virtually no fibrinogen; the major contaminant was albumin. Factor VIII related antigen was also present; the ratio of clotting activity  
25 to antigen was approximately the same as in the initial plasma (The antigen is the protein associated with the Factor VIII clotting activity).

#### Example 2

The procedure of Example 1 was repeated with the  
30 exception that, before freeze drying was carried out, the collected Factor VIII containing components were concentrated 10 to 20 fold using a hollow fibre concentrator (from





- 7 -

Amicon Corporation) with a 10,000 molecular weight cut off. The resulting concentrate was then dialysed at 4°C against .025 M Tris acetate of pH 7.5 for at least two hours before freeze drying.

- 5 The product, on redissolving in about 1/30th of the volume, from electrophoresis, of distilled water, was stable for 3 to 4 days at 4°C; also, recovery of Factor VIII activity was found to be more reproducible than by using the procedure of Example 1.



Claims

1. A method of purifying a Factor VIII containing aqueous solution characterised by the steps of
  - (i) reducing the ionic strength of the solution to a level such that it is capable of being electrophoresed;
  - (ii) adjusting the pH of the solution to within a range where the stability of Factor VIII is not adversely affected;
  - (iii) subjecting the product of step (ii) to continuous flow electrophoresis by injecting the solution, as a migrant solution, into a second aqueous solution, laminarly flowing in an annular separation chamber as a carrier solution for the migrant solution and stabilised by means of an angular velocity gradient, and applying a constant electric field across the resulting mixture to produce a differential movement of the Factor VIII component of the migrant solution with respect to the other major components of the solution perpendicular to the direction of flow of the layer; and
  - (iv) collecting the separated Factor VIII component.
2. A method according to claim 1 wherein the pH of the solution in step (ii) is adjusted to be in the range of 6 to 9.
3. A method according to claim 2 wherein the range is 7 to 8.5.
4. A method according to claim 3 wherein the pH is 7.5.
5. A method according to any of the preceding claims wherein the electrical conductivity of the solution in step (ii) is adjusted to be in the range of  $0.75$  to  $1.0 \text{ mScm}^{-1}$  at  $20^{\circ}\text{C}$ .



-9-

6. A method according to claim 1 wherein the separated Factor VIII component is further purified.
7. A method according to claim 6 wherein the further purification is effected by concentration using a hollow fibre concentrator followed by freeze drying.
8. Factor VIII prepared by a method according to claim 1.



17:14:08

# INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 78/00038

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>1</sup> According to International Patent Classification (IPC) or to both National Classification and IPC <p style="text-align: center;">C 07 G 7/00</p>								
<b>II. FIELDS SEARCHED</b> <p style="text-align: center;">Minimum Documentation Searched <sup>4</sup></p> <table border="1"> <tr> <th>Classification System</th> <th>Classification Symbols</th> </tr> <tr> <td>Int.Cl. <sup>2</sup></td> <td>C 07 G 7/00; A 61 K 35/14; A 61 K 35/16; A 61 K 37/02; A 61 K 37/04; G 01 N 27/26; B 01 D 13/02</td> </tr> </table> <p style="text-align: center;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>4</sup></p>			Classification System	Classification Symbols	Int.Cl. <sup>2</sup>	C 07 G 7/00; A 61 K 35/14; A 61 K 35/16; A 61 K 37/02; A 61 K 37/04; G 01 N 27/26; B 01 D 13/02		
Classification System	Classification Symbols							
Int.Cl. <sup>2</sup>	C 07 G 7/00; A 61 K 35/14; A 61 K 35/16; A 61 K 37/02; A 61 K 37/04; G 01 N 27/26; B 01 D 13/02							
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>14</sup> <table border="1"> <tr> <th>Category <sup>5</sup></th> <th>Citation of Document, <sup>14</sup> with indication, where appropriate, of the relevant passages <sup>17</sup></th> <th>Relevant to Claim No. <sup>18</sup></th> </tr> <tr> <td>D</td> <td>           GB, A, 1431888, published April 14, 1976,            see claim 1 and example, UNITED KINGDOM ATOMIC            ENERGY AUTHORITY              Chemical Abstracts, volume 54, no. 1, issued            January 10, 1960 (Columbus, Ohio, U.S.A.)            C.L. Johnston et al. "Isolation of (blood) co-            agulation factors by continuous flow electro-            phoresis" see column 672(b), Proc. Soc. Expl.            Biol. Med. 101, 1959, 747-50              Chemical Abstracts, volume 52, no. 21, issued Novem-            ber 10, 1958, (Columbus, Ohio, USA) Jessica H. Lewis            et al. "Application of continuous flow electro-            phoresis to the study of the blood-coagulation            proteins and the fibrinolytic enzyme system. I.            Normal human materials", see column 18751 (g,h)            J. Clin. Invest. 1958, 37, 1323-31         </td> <td>           1-8              1-8              1-8         </td> </tr> </table>			Category <sup>5</sup>	Citation of Document, <sup>14</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>18</sup>	D	GB, A, 1431888, published April 14, 1976, see claim 1 and example, UNITED KINGDOM ATOMIC ENERGY AUTHORITY  Chemical Abstracts, volume 54, no. 1, issued January 10, 1960 (Columbus, Ohio, U.S.A.) C.L. Johnston et al. "Isolation of (blood) co- agulation factors by continuous flow electro- phoresis" see column 672(b), Proc. Soc. Expl. Biol. Med. 101, 1959, 747-50  Chemical Abstracts, volume 52, no. 21, issued Novem- ber 10, 1958, (Columbus, Ohio, USA) Jessica H. Lewis et al. "Application of continuous flow electro- phoresis to the study of the blood-coagulation proteins and the fibrinolytic enzyme system. I. Normal human materials", see column 18751 (g,h) J. Clin. Invest. 1958, 37, 1323-31	1-8   1-8   1-8
Category <sup>5</sup>	Citation of Document, <sup>14</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>18</sup>						
D	GB, A, 1431888, published April 14, 1976, see claim 1 and example, UNITED KINGDOM ATOMIC ENERGY AUTHORITY  Chemical Abstracts, volume 54, no. 1, issued January 10, 1960 (Columbus, Ohio, U.S.A.) C.L. Johnston et al. "Isolation of (blood) co- agulation factors by continuous flow electro- phoresis" see column 672(b), Proc. Soc. Expl. Biol. Med. 101, 1959, 747-50  Chemical Abstracts, volume 52, no. 21, issued Novem- ber 10, 1958, (Columbus, Ohio, USA) Jessica H. Lewis et al. "Application of continuous flow electro- phoresis to the study of the blood-coagulation proteins and the fibrinolytic enzyme system. I. Normal human materials", see column 18751 (g,h) J. Clin. Invest. 1958, 37, 1323-31	1-8   1-8   1-8						
<p><sup>15</sup> Special categories of cited documents:</p> <table border="0"> <tr> <td style="vertical-align: top;"> <p>"A" document defining the general state of the art</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document cited for special reason other than those referred to in the other categories</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> </td> <td style="vertical-align: top;"> <p>"P" document published prior to the international filing date but on or after the priority date claimed</p> <p>"T" later document published on or after the international filing date or priority date and not in conflict with the application, but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance</p> </td> </tr> </table>			<p>"A" document defining the general state of the art</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document cited for special reason other than those referred to in the other categories</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p>	<p>"P" document published prior to the international filing date but on or after the priority date claimed</p> <p>"T" later document published on or after the international filing date or priority date and not in conflict with the application, but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance</p>				
<p>"A" document defining the general state of the art</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document cited for special reason other than those referred to in the other categories</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p>	<p>"P" document published prior to the international filing date but on or after the priority date claimed</p> <p>"T" later document published on or after the international filing date or priority date and not in conflict with the application, but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance</p>							
<b>IV. CERTIFICATION</b> <table border="1"> <tr> <td>           Date of the Actual Completion of the International Search <sup>2</sup>            19th February 1979         </td> <td>           Date of Mailing of this International Search Report <sup>3</sup>            23rd February 1979         </td> </tr> <tr> <td>           International Searching Authority <sup>1</sup>            European Patent Office         </td> <td>           Signature of Authorized Officer <sup>19</sup>            G.L.M. Kruidenberg         </td> </tr> </table>			Date of the Actual Completion of the International Search <sup>2</sup> 19th February 1979	Date of Mailing of this International Search Report <sup>3</sup> 23rd February 1979	International Searching Authority <sup>1</sup> European Patent Office	Signature of Authorized Officer <sup>19</sup> G.L.M. Kruidenberg		
Date of the Actual Completion of the International Search <sup>2</sup> 19th February 1979	Date of Mailing of this International Search Report <sup>3</sup> 23rd February 1979							
International Searching Authority <sup>1</sup> European Patent Office	Signature of Authorized Officer <sup>19</sup> G.L.M. Kruidenberg							

Form PCT/ISA/210 (second sheet) (October 1977)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**